NAVC, Vetstream Partner On Education


NAVC’s Thomas M. Bohn, left, and Vetstream managing director Mark Johnston.

Continuing education courses presented at the North American Veterinary Community’s conference, institute and Expeditions program will be made available online through Vetstream, the distance-learning provider reported today.

The five-year agreement calls on NAVC to record its CE classes for transfer to its new VetFolio platform. Subscribers also will have access to 15 hours of Vetacademy resources and three months of trial access to two of Vetstream’s point-of-care online references: Canis, Felis, Equis and Lapis.

The NAVC conference and trade show, set for Jan. 18 to 22 in Orlando, Fla., is expected to attract 16,000 people. More than 1,200 courses led by 350 lecturers will be offered on all aspects of veterinary medicine.

NAVC Institute, which focuses on hands-on veterinary education, is scheduled for May 18 to 23, 2014. NAVC Expeditions is a travel program that next year will take veterinarians to Rwanda and Tanzania to study wildlife, to Brazil to observe Amazon animals and to Manitoba, Canada, to monitor polar bears.

Much of what is taught will be uploaded to Vetstream.

"The new online community platform offered by NAVC will be the largest and most robust online veterinary learning portal in the world,” said NAVC’s CEO, Thomas M. Bohn.

Vetstream’s Vetacademy service features online learning and videos from providers such as the Royal (Dick) School of Veterinary Medicine in Scotland, the publisher Elsevier and the veterinary training company Improve International.

Vetstream is based in Cambridge, England.


Archive »Read More

Things You’d Love To Say To A Client, But Can’t

A veterinarian says exactly what he’s thinking in this animated VPN Video of the Week.

Abbott Wins Approval of Daily Feline Pain Drug

Simbadol may be administered once a day for pain conrol after feline surgery.

Apoquel Shortage Should End by April 2015

Zoetis apologizes for its inability to keep up with demand for a new anti-itch drug but says manufacturing improvements are underway.